Manufactured to meet the U.S. Food and Drug Administration’s (FDA) current Good Manufacturing Practice (cGMP) regulations, guidelines and recommendations. The Vector Production Facility develops and manufactures cGMP quality master cell banks and viral vectors encoding T cell receptors or chimeric antigen receptors for the ex vivo genetic modification of T lymphocytes. The trailer will also be used during the assessment of the Intravenous Admixture Unit (IVAU), which produces pain and other pharmaceuticals for the current patient population.
